NINikolay S. Ivanov

Nikolay S. Ivanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nikolay S. Ivanov has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multiparametric model of noninvasive diagnosis of neuroblastoma in children based on a novel liquid biopsy marker C18 GD2 and serum tumor markers

    by Nikolay S. Ivanov, M. Ya. Yadgarov, D. Yu. Kachanov, S. S. Larin, M. D. Mollaev, E. A. Litvin, M. A. Maschan, N. S. Grachev, T. V. Shamanskaya

    Background. Neuroblastoma (NB) is one of the most common malignant solid tumors in childhood, in some cases presenting challenges for differential diagnosis at initial presentation. Serum tumor markers – neuron-specific enolase (NSE) and lactate dehydrogenase (LDH) – have limited diagnostic accuracy. Circulating C18 lipoform of GD2 may represent a promising liquid biopsy marker for NB, however, multiparametric diagnostic models combining GD2 with serum markers remain largely unexplored. Objective – to develop and internally validate a logistic regression model for noninvasive diagnosis of NB in children based on the combination of serum C18 lipoform GD2, NSE, and LDH levels, and to assess whether a neural network model (multilayer perceptron) improves diagnostic performance compared to logistic regression. Materials and methods. Serum concentrations of C18 lipoform GD2 were measured using a validated high-performance liquid chromatography-tandem mass spectrometry method, NSE and LDH were determined by standard techniques in primary patients with suspected neurogenic tumor between July 2021 and March 2024 (32 months) at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Missing NSE and LDH data were handled by multiple imputation (m = 20). A logistic model with three continuous predictors (GD2, NSE, LDH) was fitted in each imputed dataset, and coefficients were pooled using Rubin's rules. As an alternative, a neural network model (3 inputs, one hidden layer with 2 neurons, logistic output) was trained on the 6th imputation and applied to all 20 datasets. Model performance was assessed by AUC (95% confidence interval (CI)), as well as sensitivity, specificity, positive predictive value and negative predictive value for the logistic and neural network decision rules on the pooled multiply imputed dataset at the probability threshold determined by the Youden index. Internal validation was performed using strict 5-fold cross-validation on each imputed dataset. Differences in AUC between the two decision rules were assessed using DeLong's test. Results. This prospective single-center diagnostic cohort study included 155 patients aged 0–18 years with clinical and instrumental suspicion of a neurogenic tumor prior to specific therapy (89 with NB, 66 controls). The logistic model demonstrated an AUC of 0.842 (95% CI 0.829–0.856); only C18 lipoform GD2 remained a significant predictor (OR 1.07 per 1 nM; 95% CI 1.04–1.11; p 0.001). The mean AUC under strict 5-fold cross-validation was 0.838 (range – 0.812–0.867). The neural network decision rule showed a similar AUC on pooled data (0.841; 95% CI 0.828–0.855) but a lower and more variable mean AUC under cross-validation (0.759; range – 0.684–0.841). DeLong's test revealed no statistically significant difference between the AUCs of the logistic and neural network models (p = 0.904). Conclusion. Circulating C18 lipoform GD2 may serve as a key component of the diagnostic model in patients with suspected neurogenic tumor, while NSE and LDH contribute minimal additional value. The neural network model does not provide a significant AUC advantage and is less stable than logistic regression. Given the comparable discriminatory ability, greater robustness, and interpretability, the logistic regression model was selected as the final decision rule for noninvasive NB diagnosis and implemented as an online risk calculator.

  • Open Access

    Eosinophilia and allergic reactions during immunotherapy with dinutuximab beta in patients with neuroblastoma

    by Anna V. Bykova, N. A. Andreeva, R. S. Oganesyan, I. V. Sidorov, N. S. Ivanov, D. T. Utalieva, M. V. Teleshova, O. S. Zatsarinnaya, L. A. Smirnova, R. A. Moiseenko, et al.

    Introduction. Over the past two decades, immunotherapy has become the standard of treatment for some solid malignancies in children including neuroblastoma (NB). It is a relatively safe treatment modality if appropriate supportive care is provided. However, like other treatments, immunotherapy can result in a unique toxicity profile that requires timely interpretation and appropriate management. One of the described side effects is eosinophilia that in some cases can be accompanied by adverse events affecting various organs and systems. Mechanisms of injury, critical target organs, and approaches to management are still understudied. Aim – to study the relationship between increased peripheral blood eosinophil counts and adverse events including clinical symptoms of acute tonsillitis developing during immunotherapy with dinutuximab beta in patients with NB. Being a retrospective analysis, this study did not require approval from the local Ethics Committee. Materials and methods. We retrospectively analyzed the medical history and clinical and laboratory data of 40 patients with NB who had undergone immunotherapy with dinutuximab beta as first- or second-line treatment at the Dmitry Rogachev National Medical Research Center from 2019 to 2023. Results. Eosinophilia was seen to develop between immunotherapy cycles and was accompanied by skin reactions in 47.5% of cases (in 19/40 patients) and by itchiness (14/40), bronchial obstruction syndrome (14/40) or acute tonsillitis (14/40) – in 35% of cases. From сycle to cycle, there was a tendency towards a decrease in maximum absolute eosinophil count as well as in the incidence of itchiness. At the same time, skin reactions and acute tonsillitis developed almost as frequently in the following cycles. A comparison of clinical symptoms with laboratory data revealed that eosinophilia was significantly correlated only with acute tonsillitis (p 0.05). In this study, we investigated potential causes of this condition. We reported a clinical case of acute tonsillitis that had developed during immunotherapy with dinutuximab beta confirming the hypothesis about the potential infiltration of the tonsils by eosinophils. Conclusions. One of the side effects of immunotherapy with dinutuximab beta in NB patients is non-infectious tonsillitis which can be confirmed by a histological analysis showing morphological features of eosinophilic infiltration of the palatine tonsils. A differential diagnosis between this condition and infections as well as careful monitoring of patients treated with dinutuximab beta is required for timely identification and correct interpretation of adverse reactions.

  • Open Access

    Tolerability and toxicity of induction chemoimmunotherapy with dinutuximab beta in newly diagnosed patients with high-risk neuroblastoma

    by T. V. Shamanskaya, D. Yu. Kachanov, N. S. Ivanov, L. L. Rabaeva, M. Ya. Yadgarov, O. S. Zatsarinnaya, D. T. Utalieva, D. V. Litvinov, A. G. Rumyantsev, G. A. Novichkova, et al.

    Monoclonal antibodies (mAbs) directed against GD2 are used as part of post-consolidation treatment for high-risk neuroblastoma (NB) patients with minimal residual tumor after induction therapy. It has been reported that a good end-of-induction response is associated with better event-free survival and overall survival rates. The use of mAbs in combination with chemotherapy has been shown to be effective in treating patients with relapsed NB in several international studies. Thus, the need to achieve a good end-of-induction response in high-risk NB and the feasibility of combining chemotherapy with mAbs serve as a rationale for employing immunotherapy during induction treatment of newly diagnosed patients with NB. Here, we present the results of the first Russian single-center study on the use of chemoimmunotherapy (CIT) during induction treatment in newly diagnosed patients with high-risk NB. In this prospective study carried out at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between January and August 2023, we enrolled 5 high-risk stage 4 NB patients aged 18 months. This study was approved by the Institutional Review Board and the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Healthcare of the Russian Federation (Protocol No. 10э/9-22 dated 10. 12. 2022). Therapy was carried out according to the modified GPOH NB2004 protocol. Starting from the 3rd course of induction, patients received 4 alternating courses of chemotherapy in combination with anti-G mAbs ch14.18/CHO (dinutuximab beta) at a dose of 10 mg/m2/day administered as a continuous infusion over 5 days. Toxicity was assessed as per the CTCAE 5.0 (Common Terminology Criteria for Adverse Events, version 5.0). A total of 20 courses of CIT were given. All patients completed induction therapy, with 3/5 (60%) achieving at least a partial response. There were no cases of unexpected severe toxicity or death. There were no pauses in the administration of mAb throughout all the CIT cycles, and all the patients received dinutuximab beta at full dose. Grade 3/4 toxicity was predominantly hematological. Non-hematological toxicity of grade ≥ III/IV included hypokalemia in 5/20 (25 %) courses, hypertension in 4/20 (20 %) courses and diarrhea in 3/20 (15 %) courses (due to viral infection). The need for opioid analgesics decreased with each successive course of treatment. The selected CIT regimen combining induction chemotherapy as per the GPOH NB2004 protocol and dinutuximab beta demonstrated safety and acceptable toxicity in newly diagnosed patients with high-risk stage 4 NB older than 18 months. Further multicenter cooperative studies will allow for the development of the optimal induction regimen consisting of chemotherapy and mAbs for improved survival in patients with high-risk NB.


  • Open Access

    Neuroblastoma chemoimmunotherapy: current results and application prospects

    by N. S. Ivanov, D. Yu. Kachanov, T. V. Shamanskaya

    Neuroblastoma (NB) is the most common extracranial solid tumor of childhood affecting children from 0 to 14 years old. Despite the achievements of modern multimodal risk-adapted therapy, the prognosis in patients with high-risk NB remains unfavorable. Numerous research groups have shown that a good response achieved at the time of completion of the induction stage of therapy in this subgroup of patients correlates with survival rates. Thus, improving the response to induction therapy may be a potential mechanism for improving long-term survival rates. Over the past few decades, traditional approaches to cancer therapy have undergone a radical revolution, largely due to the development and implementation of the immunotherapy method. It is known that combined antitumor therapy is superior to monotherapy and is one of the tools for overcoming heterogeneous drug resistance. A vast number of preclinical studies has shown that GD2-directed monoclonal antibodies (mAbs) are able to enhance the cytostatic effects of chemotherapeutic drugs, which has become a promising model for clinical studies of various chemoimmunotherapy regimens, which have demonstrated convincing evidence of safety and an acceptable toxicity profile with an encouraging effect on objective response rates, overall and event-free survival in both patients with recurrent, refractory NB, and primary patients of the high-risk group.The article discusses fundamental ideas about the synergistic interaction of GD2-directed mAbs in combination with cytostatic agents, the role of response to the induction stage of therapy and prospects for the use of induction chemoimmunotherapy as a method of improving postinduction response, event-free and overall survival in patients with NB.


  • Open Access

    The role of GD2 as a diagnostic and prognostic tumor marker in neuroblastoma (literature review)

    by N. S. Ivanov, D. Y. Kachanov, S. S. Larin, M. D. Mollaev, D. M. Konovalov, T. V. Shamanskaya

    Роль GD2 как диагностического и прогностического опухолевого маркера при нейробластоме (обзор литературы)


  • Open Access

    The role of gangliosides in the modulation of carcinogenesis

    by N. S. Ivanov, R. V. Kholodenko, D. Yu. Kachanov, S. S. Larin, M. D. Mollaev, T. V. Shamanskaya

    Gangliosides are complex glycosphingolipids which contain ceramide and various oligosaccharides usually bearing sialic acids. An interesting feature of gangliosides is that their quantitative and qualitative composition changes during oncogenesis. This process is specific and depends on the histological type of a tumor and its functional status even within one neoplasm. On the other hand, latest advances in understanding structural and functional organization of glycosphingolipids, and primarily insights into lipid raft formation, showed that gangliosides may take part in the regulation of the activity of kinases mediating the modulation of signaling pathways involved in the malignant potential of cells. This article describes basic concepts of gangliosides and their biological role in signaling pathways involved in tumor development. We focused on experimental studies revealing both inhibitory and activating effects on important protein receptors responsible for cell proliferation, differentiation and death.


  • Open Access

    Сongenital infantile fibrosarcoma with a non-canonical TPM3-NTRK1 fusion transcript: a case report and a literature review

    by N. S. Ivanov, A. V. Panfyorova, D. M. Konovalov, M. V. Teleshova, N. A. Bolshakov, T. V. Shamanskaya, A. E. Druy, D. Yu. Kachanov

    Infantile fibrosarcoma (IFS) is a rare malignant soft tissue tumor characterized by local invasion, a low rate of distant metastasis (1–13%), and manifestation during the first years of life. Overall survival rates range from 89 to 94%, event-free survival rates – from 81 to 84%. Classic IFS is characterized by t(12;15)(p13;q25) translocation resulting in the formation of the ETV6-NTRK3 fusion transcript. However, over the past few years, there have been numerous reports of IFS-like tumors with non-canonical genetic aberrations (BRAF, NTRK1, MET genes) whose prognosis is less predictable. Here we report a rare case of congenital IFS with involvement of subcutaneous fat, indolent course and a non-canonical TPM3-NTRK1 fusion transcript identified in the soft tissue and intradermal tumor components with different histological features. The patient’s parents gave their consent to the use of their child’s data, including photographs, for research purposes and in publications. The literature review explores modern algorithms for the diagnosis and treatment of IFS in children, including the use of new therapies, such as tropomyosin receptor kinase inhibitors, as well as algorithms for detecting NTRK1, NTRK2, NTRK3 gene rearrangements in solid neoplasms in general, and soft tissue tumors in particular.